Clinical Trials Browser

Interventional × Hereditary Sensory and Autonomic Neuropathies × Lymphoid × Clear all

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT03126019 2025-03-14

CITADEL-203

Phase 2 Completed

126 enrolled 15 charts

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Hereditary Sensory and Autonomic Neuropathies

NCT02204982 2023-09-28

DYNAMO + R

Phase 3 Terminated

13 enrolled 10 charts 2 FDA

Lymphoid

Lymphoma, Follicular, Hereditary Sensory and Autonomic Neuropathies

NCT02292225 2023-02-27

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Phase 1 Terminated

3 enrolled

LymphoidOther hematologic neoplasm

Hereditary Sensory and Autonomic Neuropathies, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03074825 2019-07-24

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Phase 1 Terminated

5 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Hereditary Sensory and Autonomic Neuropathies, Recurrence

NCT01341834 2018-04-24

Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors

Phase 1 Unknown

49 enrolled

Head & NeckLymphoid

Nasopharyngeal Carcinoma, Lymphoma, Hereditary Sensory and Autonomic Neuropathies

NCT02598570 2017-02-06

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

Phase 1 Completed

7 enrolled

Lymphoid

Lymphoma, Hereditary Sensory and Autonomic Neuropathies

Clinical Trials

9-ING-41 in Patients With Advanced Cancers

CITADEL-203

DYNAMO + R

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma